[go: up one dir, main page]

HUP0102880A3 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
HUP0102880A3
HUP0102880A3 HU0102880A HUP0102880A HUP0102880A3 HU P0102880 A3 HUP0102880 A3 HU P0102880A3 HU 0102880 A HU0102880 A HU 0102880A HU P0102880 A HUP0102880 A HU P0102880A HU P0102880 A3 HUP0102880 A3 HU P0102880A3
Authority
HU
Hungary
Prior art keywords
coadministration
acat
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
HU0102880A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0102880A2 publication Critical patent/HUP0102880A2/hu
Publication of HUP0102880A3 publication Critical patent/HUP0102880A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
HU0102880A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions HUP0102880A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (2)

Publication Number Publication Date
HUP0102880A2 HUP0102880A2 (en) 2002-06-29
HUP0102880A3 true HUP0102880A3 (en) 2002-11-28

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102880A HUP0102880A3 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (et)
JP (1) JP2002521328A (et)
KR (1) KR20010083134A (et)
CN (1) CN1310629A (et)
AP (1) AP2001002035A0 (et)
AU (1) AU4701799A (et)
BG (1) BG105162A (et)
BR (1) BR9912296A (et)
CA (1) CA2335062A1 (et)
CZ (1) CZ2001126A3 (et)
EA (1) EA200100153A1 (et)
EE (1) EE200100046A (et)
HR (1) HRP20010055A2 (et)
HU (1) HUP0102880A3 (et)
ID (1) ID30030A (et)
IL (1) IL140982A0 (et)
IS (1) IS5809A (et)
NO (1) NO20010291D0 (et)
OA (1) OA11584A (et)
PL (1) PL346011A1 (et)
SK (1) SK502001A3 (et)
TR (1) TR200100205T2 (et)
WO (1) WO2000004892A2 (et)
YU (1) YU3501A (et)
ZA (1) ZA200100294B (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513909A (ja) * 1999-11-05 2003-04-15 ワーナー−ランバート・カンパニー Ａｃａｔ阻害剤によるプラーク破裂の予防
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
WO2001044179A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DE60321775D1 (de) * 2002-04-03 2008-08-07 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
EP1539744A4 (en) * 2002-07-11 2007-06-06 Vicuron Pharm Inc N-HYDROXYAMIDE DERIVATIVES WITH ANTIBACTERIAL EFFECT
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
KR19990036127A (ko) * 1995-08-03 1999-05-25 로즈 암스트롱 지방단백질의 농도를 감소시키는 의약의 제조를 위한 술팜산 유도체, 아실 술폰아미드 또는 술포닐 카르바메이트의 용도
EP0901466B1 (en) * 1996-05-17 2001-10-31 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos

Also Published As

Publication number Publication date
KR20010083134A (ko) 2001-08-31
IL140982A0 (en) 2002-02-10
SK502001A3 (en) 2002-06-04
WO2000004892A2 (en) 2000-02-03
CZ2001126A3 (cs) 2002-01-16
EP1098662A2 (en) 2001-05-16
HUP0102880A2 (en) 2002-06-29
BR9912296A (pt) 2001-04-17
CA2335062A1 (en) 2000-02-03
ZA200100294B (en) 2002-01-10
EA200100153A1 (ru) 2001-08-27
AU4701799A (en) 2000-02-14
OA11584A (en) 2004-07-20
BG105162A (en) 2001-12-29
ID30030A (id) 2001-11-01
PL346011A1 (en) 2002-01-14
NO20010291L (no) 2001-01-18
AP2001002035A0 (en) 2001-03-31
CN1310629A (zh) 2001-08-29
WO2000004892A3 (en) 2000-05-18
YU3501A (sh) 2005-06-10
EE200100046A (et) 2002-06-17
TR200100205T2 (tr) 2001-05-21
IS5809A (is) 2001-01-12
JP2002521328A (ja) 2002-07-16
NO20010291D0 (no) 2001-01-18
HRP20010055A2 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
GB9800795D0 (en) Prevention of multiple use of limited use devices
AU3034300A (en) Substituted benzimidazoles and their use as parp inhibitors
AU2212299A (en) Compositions and methods for the treatment of tumor
HU0900792D0 (en) Use of renin-angiotensin inhibitors
PL341335A1 (en) Combination of ace and mmp inhibitors
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
GB2342045B (en) Mineral and vitamin combinations for the treatment of stress and allergies
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
HUP0102880A2 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IT1302811B1 (it) Procedimento e relativo apparato per la riduzione direttadi ossidi di ferro
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
PL348029A1 (en) Fluticasone lotion having improved vasoconstrictor activity
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
AU1940800A (en) Combination therapy for the treatment of sepsis
GB2343629B (en) Treatment of cellulite
EP1135141A4 (en) PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER